Viruses of the Ebolavirus genus cause sporadic epidemics of severe and systemic febrile
disease that are fueled by human-to-human transmission. Despite the notoriety of …

There are no approved drugs or biologics to treat Ebola virus disease (EVD). Literature
reviews identified a list of 141 drugs with reports of preliminary in vitro potency and in vivo …

The pathophysiology of long-recognized hematologic abnormalities in Ebolavirus (EBOV)
disease (EVD) is unknown. From limited human sampling (of peripheral blood), it has been …

The 2014 to 2016 Ebola outbreak, primarily based in 3 West African countries, had far-
reaching global effects. Importantly, the crisis highlighted large gaps in reproductive health …

The recent Ebola virus disease (EVD) outbreak in West Africa in 2014 to 2016 highlighted
the capabilities of dedicated biocontainment units (BCUs) at the National Institutes of Health …

Background There are currently limited data for the use of specific antiviral therapies for the
treatment of Ebola virus disease (EVD). While there is anecdotal evidence that supportive …

Like most viral illnesses in humans, supportive care of the patient is the mainstay of clinical
care for patients with Ebola virus disease (EVD). The goal is to maintain and sustain the …

RESUMO O EBOV representa um dos vírus mais perigosos e mortais que existe a nível
mundial, podendo afetar os humanos e determinados animais, como por exemplo os …

The outbreak of Ebola virus disease (EVD) centered in the West African countries of Guinea,
Liberia, and Sierra Leone from 2013-2016 was the longest and largest such outbreak on …

Background: 2019-nCoV has posed a significant threat to human health since the epidemic
began. So far, there is no definite safe and effective drug treatment. Proper management can …